Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic evidence of EoE~* Clinical symptoms of EoE including dysphagia~Exclusion Criteria:~* Primary causes of esophageal eosinophilia other than EoE

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- RPC4046 Low Dose (Type: EXPERIMENTAL): intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, low dose
- RPC4046 High Dose (Type: EXPERIMENTAL): intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, high dose
- Placebo (Type: PLACEBO_COMPARATOR): intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).